Perfluoroalkyl substances and lipid concentrations in plasma during pregnancy among women in the Norwegian Mother and Child Cohort Study

Environment International

Volumn 62, Issue , 2014, Pages 104-112

  Starling, Anne P ^a,b   Engel, Stephanie M ^b   Whitworth, Kristina W ^c   Richardson, David B ^b   Stuebe, Alison M ^b,d   Daniels, Julie L ^b   Haug, Line Småstuen ^e   Eggesbø, Merete ^e   Becher, Georg ^e   Sabaredzovic, Azemira ^e   Thomsen, Cathrine ^e   Wilson, Ralph E ^a   Travlos, Gregory S ^e   Hoppin, Jane A ^a   Baird, Donna D ^a   Longnecker, Matthew P ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b IL   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

MoBa; Perfluoroalkyl substances; Perfluorooctane sulfonate; Perfluorooctanoic acid; The Norwegian Mother and Child Cohort Study

Indexed keywords

LIPOPROTEINS; OBSTETRICS; PLASMAS;

COHORT STUDIES; MOBA; PERFLUOROALKYL SUBSTANCES; PERFLUOROOCTANE SULFONATES; PERFLUOROOCTANOIC ACID;

CHOLESTEROL;

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERFLUORO COMPOUND; PERFLUOROALKYL SUBSTANCE; PERFLUORODECANOIC ACID; PERFLUOROHEPTANE SULFONATE; PERFLUOROHEXANE SULFONATE; PERFLUORONONANOIC ACID; PERFLUOROOCTANESULFONIC ACID; PERFLUOROOCTANOIC ACID; PERFLUOROUNDECANOIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

BLOOD; COHORT ANALYSIS; CONCENTRATION (COMPOSITION); LIPID; PLASMA; POLLUTANT; PREGNANCY; PROTEIN; SULFONATE; WOMENS HEALTH;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; NORWAY; PREGNANT WOMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

NORWAY;

EID: 84887144561     PISSN: 01604120     EISSN: 18736750     Source Type: Journal    
DOI: 10.1016/j.envint.2013.10.004     Document Type: Article

References (64)

1. Abbott B.D., Wolf C.J., Schmid J.E., Das K.P., Zehr R.D., Helfant L., et al. Perfluorooctanoic acid induced developmental toxicity in the mouse is dependent on expression of peroxisome proliferator activated receptor-alpha. Toxicol Sci 2007, 98:571-581.
2. Abbott B.D., Wolf C.J., Das K.P., Zehr R.D., Schmid J.E., Lindstrom A.B., et al. Developmental toxicity of perfluorooctane sulfonate (PFOS) is not dependent on expression of peroxisome proliferator activated receptor-alpha (PPAR alpha) in the mouse. Reprod Toxicol 2009, 27:258-265.
3. Aurell M., Cramer K. Serum lipids and lipoproteins in human pregnancy. Clin Chim Acta 1966, 13:278-284.
4. Baker A.M., Klein R.L., Moss K.L., Haeri S., Boggess K. Maternal serum dyslipidemia occurs early in pregnancy in women with mild but not severe preeclampsia. Am J Obstet Gynecol 2009, 201(293):e291-e294.
5. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316.
6. Bartell S.M., Calafat A.M., Lyu C., Kato K., Ryan P.B., Steenland K. Rate of decline in serum PFOA concentrations after granular activated carbon filtration at two public water systems in Ohio and West Virginia. Environ Health Perspect 2010, 118:222-228.
7. Bayhan G., Kocyigit Y., Atamer A., Atamer Y., Akkus Z. Potential atherogenic roles of lipids, lipoprotein(a) and lipid peroxidation in preeclampsia. Gynecol Endocrinol 2005, 21:1-6.
8. Beesoon S., Genuis S.J., Benskin J.P., Martin J.W. Exceptionally high serum concentrations of perfluorohexanesulfonate in a Canadian family are linked to home carpet treatment applications. Environ Sci Technol 2012, 46:12960-12967.
9. Brantsaeter A.L., Whitworth K.W., Ydersbond T.A., Haug L.S., Haugen M., Knutsen H.K., et al. Determinants of plasma concentrations of perfluoroalkyl substances in pregnant Norwegian women. Environ Int 2013, 54C:74-84.
10. Butenhoff J.L., Pieterman E., Ehresman D.J., Gorman G.S., Olsen G.W., Chang S.C., et al. Distribution of perfluorooctanesulfonate and perfluorooctanoate into human plasma lipoprotein fractions. Toxicol Lett 2012, 210:360-365.
11. Chateau-Degat M.L., Pereg D., Dallaire R., Ayotte P., Dery S., Dewailly E. Effects of perfluorooctanesulfonate exposure on plasma lipid levels in the Inuit population of Nunavik (Northern Quebec). Environ Res 2010, 110:710-717.
12. Clark S., Youngman L.D., Palmer A., Parish S., Peto R., Collins R. Stability of plasma analytes after delayed separation of whole blood: implications for epidemiological studies. Int J Epidemiol 2003, 32:125-130.
13. Costa G., Sartori S., Consonni D. Thirty years of medical surveillance in perfluooctanoic acid production workers. J Occup Environ Med 2009, 51:364-372.
14. Davis C.E., Rifkind B.M., Brenner H., Gordon D.J. A single cholesterol measurement underestimates the risk of coronary heart disease. An empirical example from the Lipid Research Clinics Mortality Follow-up Study. JAMA 1990, 264:3044-3046.
15. DeWitt J.C., Shnyra A., Badr M.Z., Loveless S.E., Hoban D., Frame S.R., et al. Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. Crit Rev Toxicol 2009, 39:76-94.
16. Ehresman D.J., Froehlich J.W., Olsen G.W., Chang S.C., Butenhoff J.L. Comparison of human whole blood, plasma, and serum matrices for the determination of perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and other fluorochemicals. Environ Res 2007, 103:176-184.
17. Enquobahrie D.A., Williams M.A., Butler C.L., Frederick I.O., Miller R.S., Luthy D.A. Maternal plasma lipid concentrations in early pregnancy and risk of preeclampsia. Am J Hypertens 2004, 17:574-581.
18. Fahraeus L., Larsson-Cohn U., Wallentin L. Plasma lipoproteins including high density lipoprotein subfractions during normal pregnancy. Obstet Gynecol 1985, 66:468-472.
19. Fei C., McLaughlin J.K., Tarone R.E., Olsen J. Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort. Environ Health Perspect 2007, 115:1677-1682.
20. Fisher M., Arbuckle T.E., Wade M., Haines D.A. Do perfluoroalkyl substances affect metabolic function and plasma lipids? - Analysis of the 2007-2009, Canadian Health Measures Survey (CHMS) Cycle 1. Environ Res 2013, 121:95-103.
21. Frisbee S.J., Shankar A., Knox S.S., Steenland K., Savitz D.A., Fletcher T., et al. Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents: results from the C8 Health Project. Arch Pediatr Adolesc Med 2010, 164:860-869.
22. Frömel T., Knepper T.P. Biodegradation of fluorinated alkyl substances. Rev Environ Contam Toxicol 2010, 208:161-177.
23. Fromme H., Tittlemier S.A., Volkel W., Wilhelm M., Twardella D. Perfluorinated compounds - exposure assessment for the general population in Western countries. Int J Hyg Environ Health 2009, 212:239-270.
24. Fromme H., Mosch C., Morovitz M., Alba-Alejandre I., Boehmer S., Kiranoglu M., et al. Pre- and postnatal exposure to perfluorinated compounds (PFCs). Environ Sci Technol 2010, 44:7123-7129.
25. Giesy J.P., Kannan K. Perfluorochemical surfactants in the environment. Environ Sci Technol 2002, 36:146A-152A.
26. Glynn A., Berger U., Bignert A., Ullah S., Aune M., Lignell S., et al. Perfluorinated alkyl acids in blood serum from primiparous women in Sweden: serial sampling during pregnancy and nursing, and temporal trends 1996-2010. Environ Sci Technol 2012, 46:9071-9079.
27. Haug L.S., Thomsen C., Becher G. A sensitive method for determination of a broad range of perfluorinated compounds in serum suitable for large-scale human biomonitoring. J Chromatogr A 2009, 1216:385-393.
28. Haug L.S., Thomsen C., Becher G. Time trends and the influence of age and gender on serum concentrations of perfluorinated compounds in archived human samples. Environ Sci Technol 2009, 43:2131-2136.
29. Haug L.S., Thomsen C., Brantsaeter A.L., Kvalem H.E., Haugen M., Becher G., et al. Diet and particularly seafood are major sources of perfluorinated compounds in humans. Environ Int 2010, 36:772-778.
30. Haug L.S., Huber S., Becher G., Thomsen C. Characterisation of human exposure pathways to perfluorinated compounds - comparing exposure estimates with biomarkers of exposure. Environ Int 2011, 37:687-693.
31. Hayek T., Ito Y., Azrolan N., Verdery R.B., Aalto-Setala K., Walsh A., et al. Dietary fat increases high density lipoprotein (HDL) levels both by increasing the transport rates and decreasing the fractional catabolic rates of HDL cholesterol ester and apolipoprotein (Apo) A-I. Presentation of a new animal model and mechanistic studies in human Apo A-I transgenic and control mice. J Clin Invest 1993, 91:1665-1671.
32. Hertz R., Bishara-Shieban J., Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem 1995, 270:13470-13475.
33. Irgens L.M. The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30years. Acta Obstet Gynecol Scand 2000, 79:435-439.
34. Javins B., Hobbs G., Ducatman A.M., Pilkerton C., Tacker D., Knox S.S. Circulating maternal perfluoroalkyl substances during pregnancy in the C8 Health Study. Environ Sci Technol 2013, 47:1606-1613.
35. Kannan K., Corsolini S., Falandysz J., Fillmann G., Kumar K.S., Loganathan B.G., et al. Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. Environ Sci Technol 2004, 38:4489-4495.
36. Kato K., Wong L.Y., Jia L.T., Kuklenyik Z., Calafat A.M. Trends in exposure to polyfluoroalkyl chemicals in the U.S. population: 1999-2008. Environ Sci Technol 2011, 45:8037-8045.
37. Kato K., Wong L.Y., Basden B.J., Calafat A.M. Effect of temperature and duration of storage on the stability of polyfluoroalkyl chemicals in human serum. Chemosphere 2013, 91:115-117.
38. Kennedy G.L., Butenhoff J.L., Olsen G.W., O'Connor J.C., Seacat A.M., Perkins R.G., et al. The toxicology of perfluorooctanoate. Crit Rev Toxicol 2004, 34:351-384.
39. Langsted A., Freiberg J.J., Nordestgaard B.G. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008, 118:2047-2056.
40. Lau C., Anitole K., Hodes C., Lai D., Pfahles-Hutchens A., Seed J. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci 2007, 99:366-394.
41. Llurba E., Casals E., Dominguez C., Delgado J., Mercade I., Crispi F., et al. Atherogenic lipoprotein subfraction profile in preeclamptic women with and without high triglycerides: different pathophysiologic subsets in preeclampsia. Metabolism 2005, 54:1504-1509.
42. Loccisano A.E., Longnecker M.P., Campbell J.L., Andersen M.E., Clewell H.J. Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages. J Toxicol Environ Health A 2013, 76:25-57.
43. Magnus P., Irgens L.M., Haug K., Nystad W., Skjaerven R., Stoltenberg C., et al. Cohort profile: the Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol 2006, 35:1146-1150.
44. Mensink R.P., Zock P.L., Kester A.D., Katan M.B. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003, 77:1146-1155.
45. Nelson J.W., Hatch E.E., Webster T.F. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. Environ Health Perspect 2010, 118:197-202.
46. Nilsen R.M., Vollset S.E., Gjessing H.K., Skjaerven R., Melve K.K., Schreuder P., et al. Self-selection and bias in a large prospective pregnancy cohort in Norway. Paediatr Perinat Epidemiol 2009, 23:597-608.
47. Olsen G.W., Burris J.M., Burlew M.M., Mandel J.H. Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J Occup Environ Med 2003, 45:260-270.
48. Olsen G.W., Burris J.M., Ehresman D.J., Froehlich J.W., Seacat A.M., Butenhoff J.L., et al. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 2007, 115:1298-1305.
49. Piechota W., Staszewski A. Reference ranges of lipids and apolipoproteins in pregnancy. Eur J Obstet Gynecol Reprod Biol 1992, 45:27-35.
50. Prevedouros K., Cousins I.T., Buck R.C., Korzeniowski S.H. Sources, fate and transport of perfluorocarboxylates. Environ Sci Technol 2006, 40:32-44.
51. Richardson D.B., Ciampi A. Effects of exposure measurement error when an exposure variable is constrained by a lower limit. Am J Epidemiol 2003, 157:355-363.
52. Richardson D.B., Rzehak P., Klenk J., Weiland S.K. Analyses of case-control data for additional outcomes. Epidemiology 2007, 18:441-445.
53. Rønningen K.S., Paltiel L., Meltzer H.M., Nordhagen R., Lie K.K., Hovengen R., et al. The biobank of the Norwegian Mother and Child Cohort Study: a resource for the next 100years. Eur J Epidemiol 2006, 21:619-625.
54. Sakr C.J., Kreckmann K.H., Green J.W., Gillies P.J., Reynolds J.L., Leonard R.C. Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers. J Occup Environ Med 2007, 49:1086-1096.
55. Sattar N., Bendomir A., Berry C., Shepherd J., Greer I.A., Packard C.J. Lipoprotein subfraction concentrations in preeclampsia: pathogenic parallels to atherosclerosis. Obstet Gynecol 1997, 89:403-408.
56. Sattar N., Greer I.A., Louden J., Lindsay G., McConnell M., Shepherd J., et al. Lipoprotein subfraction changes in normal pregnancy: threshold effect of plasma triglyceride on appearance of small, dense low density lipoprotein. J Clin Endocrinol Metab 1997, 82:2483-2491.
57. Savitz D.A., Stein C.R., Bartell S.M., Elston B., Gong J., Shin H.M., et al. Perfluorooctanoic acid exposure and pregnancy outcome in a highly exposed community. Epidemiology 2012, 23:386-392.
58. Soudijn W., van Wijngaarden I., Ijzerman A.P. Nicotinic acid receptor subtypes and their ligands. Med Res Rev 2007, 27:417-433.
59. Steenland K., Tinker S., Frisbee S., Ducatman A., Vaccarino V. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. Am J Epidemiol 2009, 170:1268-1278.
60. Vrijkotte T.G., Krukziener N., Hutten B.A., Vollebregt K.C., van Eijsden M., Twickler M.B. Maternal lipid profile during early pregnancy and pregnancy complications and outcomes: the ABCD study. J Clin Endocrinol Metab 2012, 97:3917-3925.
61. Wang J., Zhang Y., Zhang W., Jin Y., Dai J. Association of perfluorooctanoic acid with HDL cholesterol and circulating miR-26b and miR-199-3p in workers of a fluorochemical plant and nearby residents. Environ Sci Technol 2012, 46:9274-9281.
62. Whitworth K.W., Haug L.S., Baird D.D., Becher G., Hoppin J.A., Skjaerven R., et al. Perfluorinated compounds and subfecundity in pregnant women. Epidemiology 2012, 23:257-263.
63. Wolf C.J., Schmid J.E., Lau C., Abbott B.D. Activation of mouse and human peroxisome proliferator-activated receptor-alpha (PPARalpha) by perfluoroalkyl acids (PFAAs): further investigation of C4-C12 compounds. Reprod Toxicol 2012, 33:546-551.
64. Woodruff T.J., Zota A.R., Schwartz J.M. Environmental chemicals in pregnant women in the United States: NHANES 2003-2004. Environ Health Perspect 2011, 119:878-885.